Abstract
We report anextremely rare case of Kappa light chain myeloma in a 70 year old female who presented with pancytopenia. Light chain myeloma is characterized by the inability of the malignant plasma cells to produce heavy chains, resulting in the exclusive production of light chains.. Light chain myeloma tends to have a poor outlook compared to other myelomas since it’s frequently more aggressive and often presents with Renal failure. Worldwide incidence of Light chain myeloma is approximately 15-20% among multiple myeloma patients. The incidence of lambda light chain myeloma is predominant among light chain myelomas.
Keywords: Plasma cell dyscrasia,Kappa light chain, Light chain myeloma
References
- Wolpert, J., & Levin, M. (2021, May 24). Light Chain Multiple Myeloma: Your Ultimate Guide. MyMyelomaTeam
- https://www.mymyelomateam.com/resources/light-chain-multiple-myeloma-your-ultimate-guide
- Rafae A, Malik MN, Abu Zar M, Durer S, Durer C. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring. Cureus. 2018 Aug 15;10(8):e3148. doi: 10.7759/cureus.3148. PMID: 30345204; PMCID: PMC6191009.
- Magrangeas, F., Cormier, M. L., Descamps, G., Gouy, N., Lodé, L., Mellerin, M. P., Harousseau, J. L., Bataille, R., Minvielle, S., &Avet-Loiseau, H. (2004). Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood, 103(10),3869–3875. https://doi.org/10.1182/blood-2003-07-2501
- Silva C, Costa A, Paiva D, et al. (October 29, 2021) Light-Chain Multiple Myeloma: A Diagnostic Challenge. Cureus 13(10): e19131. doi:10.7759/cureus.19131
- Pavan M, Ashwini KA, Ravi R, Suratkal LH. Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids. Indian J Nephrol. 2010 Apr;2 0(2):94-6. doi: 10.4103/0971-4065.65304. PMID: 20835325; PMCID: PMC2931142.
- Soh KT, Tario JD Jr, Wallace PK. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry. Clin Lab Med. 2017 Dec;37(4):821-853. doi: 10.1016/j.cll.2017.08.001. PMID: 29128071; PMCID: PMC5804349.
Corresponding Author
Dr Aakash T. Ajith
Post Graduate, Department of General Medicine, Sri Manakula Vinayagar Medical College and Hospital
DOI: https://dx.doi.org/10.18535/jmscr/v10i9.13
